Benuvia Operations Drug Patent Portfolio
Benuvia Operations owns 1 orange book drug protected by 4 US patents Given below is the list of Benuvia Operations's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10265293 | Oral cannabinoid formulations | 06 Aug, 2028 | Active |
| US11253472 | Oral cannabinoid formulations | 06 Aug, 2028 | Active |
| US8222292 | Liquid cannabinoid formulations | 06 Aug, 2028 | Active |
| US9345771 | Oral cannabinoid formulations | 06 Aug, 2028 | Active |
Latest Legal Activities on Benuvia Operations's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Benuvia Operations.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Yr, Small Entity | 20 Nov, 2023 | US8222292 (Litigated) |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 21 Jul, 2022 | US10265293 |
|
Email Notification
Critical
| 20 Jul, 2022 | US10265293 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 20 Jul, 2022 | US10265293 |
|
Correspondence Address Change
Critical
| 19 Jul, 2022 | US10265293 |
|
Recordation of Patent Grant Mailed
Critical
| 22 Feb, 2022 | US11253472 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 22 Feb, 2022 | US11253472 |
|
Email Notification
Critical
| 03 Feb, 2022 | US11253472 |
|
Issue Notification Mailed
Critical
| 02 Feb, 2022 | US11253472 |
|
Application Is Considered Ready for Issue
Critical
| 14 Jan, 2022 | US11253472 |
| Dispatch to FDC | 14 Jan, 2022 | US11253472 |
|
Issue Fee Payment Verified
Critical
| 12 Jan, 2022 | US11253472 |
|
Issue Fee Payment Received
Critical
| 12 Jan, 2022 | US11253472 |
| Response to Reasons for Allowance | 12 Jan, 2022 | US11253472 |
|
Electronic Review
Critical
| 15 Oct, 2021 | US11253472 |
Benuvia Operations's Family Patents
Benuvia Operations drugs have patent protection in a total of 4 countries. It has a significant patent presence in the US with 72.7% of its patents being US patents. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Benuvia Operations Drug List
Given below is the complete list of Benuvia Operations's drugs and the patents protecting them.
1. Syndros
Syndros is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10265293 | Oral cannabinoid formulations |
06 Aug, 2028
(3 years from now)
| Active |
| US11253472 | Oral cannabinoid formulations |
06 Aug, 2028
(3 years from now)
| Active |
| US8222292 | Liquid cannabinoid formulations |
06 Aug, 2028
(3 years from now)
| Active |
| US9345771 | Oral cannabinoid formulations |
06 Aug, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Syndros's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List